+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 0 - 18Years
All Genders
ID07857746

Outcomes of Hematopoietic Stem Cell Transplantation in Children with Blood Diseases, Cancers, and Genetic Conditions at Ramathibodi Hospital

Led by Mahidol University · Updated on 2026-10-05

200

Participants Needed

1

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying hematopoietic stem cell transplantation HSCT outcomes in children with blood diseases, cancers, and other conditions such as Gaucher disease at the Pediatric Department of Ramathibodi Hospital. The goal is to understand how different factors affect treatment results and to improve care by studying complications after HSCT. The transplantation mainly uses stem cells from donors with matching human leukocyte antigen HLA types, including siblings or volunteers. The hospital also performs HSCT using partially matched donors like parents when fully matched donors are unavailable. Key parts of treatment include preparing patients before transplantation, choosing the right chemotherapy regimen before transplant, and providing careful care during and after the procedure. Participants will be monitored over time to collect data about survival rates, disease-free periods, complications like graft-versus-host disease, and infection rates up to five years after HSCT. This information will help improve patient preparation and treatment planning for better outcomes. The study runs from 2020 to 2035, focusing on long-term results in children up to 18 years old who have undergone HSCT for these diseases.

CONDITIONS

Brief Title

Outcome of HSCT in Children at Ramathibodi Hospital

Research Team

U

Usanarat Anurathapan, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here